Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting

References

• Kronenberg S, Baumann A, de Haan L, Hinton HJ, Moggs J, Theil FP, Wakefield I, Singer T. Current challenges and opportunities in nonclinical safety testing of biologics. Drug Discov Today. 2013;18(23–24):1138–17. doi:10.1016/j.drudis.2013.08.003.
   PubMed Web of Science ®Google Scholar
• Baumann A, Flagella K, Forster R, de Haan L, Kronenberg S, Locher M, Richter WF, Theil FP, Todd M. New challenges and opportunities in nonclinical safety testing of biologics. Reg Tox Pharm. 2015;69(2):226–33. doi:10.1016/j.yrtph.2014.04.005.
   Web of Science ®Google Scholar
• Brennan FR, Baumann A, Blaich G, de Haan L, Fagg R, Kiessling A, Kronenberg S, Locher M, Milton M, Tibbits J. Nonclinical safety testing of biopharmaceuticals – addressing current challenges of these novel and emerging therapies. Reg Tox Pharm. 2015;73(1):265–75. doi:10.1016/j.yrtph.2015.07.019.
   PubMed Web of Science ®Google Scholar
• Blaich G, Baumann A, Kronenberg S, de Haan L, Ulrich P, Richter WF, Tibbits J, Chivers S, Tarcsa E, Caldwell R. Non-clinical safety evaluation of biotherapeutics – challenges, opportunities and new insights. Reg Tox Pharm. 2016;80:1–14. doi:10.1016/j.yrtph.2016.08.012.
   PubMed Web of Science ®Google Scholar
• Ulrich P, Blaich G, Baumann A, Fagg R, Hey A, Kiessling A, Kronenberg S, Hvid Lindecrona R, Mohl S, Richter WF. Biotherapeutics in non-clinical development: strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing. Reg Tox Pharm. 2018;94:91–100. doi:10.1016/j.yrtph.2018.01.013.
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML. Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura. Expert Rev Clin Pharmacol. 2019;12(6):537–45. doi:10.1080/17512433.2019.1607293.
   PubMed Web of Science ®Google Scholar
• Wehner NG, Shopp G, Rocca MS, Clarke J. Effects of natalizumab, an alpha4 integrin inhibitor, on the development of hartley guinea pigs. Birth Defects Res B Dev Reprod Toxico. 2009;86(2):98–107. doi:10.1002/bdrb.20189.
   PubMedGoogle Scholar
• Wehner NG, Skov M, Shopp G, Rocca MS, Clarke J. Effects of natalizumab, an alpha4 integrin inhibitor, on fertility in male and female guinea pigs. Birth Defects Res B Dev Reprod Toxicol. 2009;86(2):108–16. doi:10.1002/bdrb.20191.
   PubMedGoogle Scholar
• Krayer JA Unique Toxicology development program: tremfya an anti-IL23 inhibitor for the treatment of psoriasis and other indications. Presented at: Charles River 24th Annual Biotech symposium: Biotechnology-derived therapeutics. Perspectives on non-clinical development; 2018 Sep; La Jolla, CA.
   Google Scholar
• Suckow M, Stevens K, Wilson R, The laboratory rabbit, guinea pig, hamster, and other rodents. American College of Laboratory Animal Medicine. 2012;1288. Elsevier Inc. doi:10.1016/C2009-0-30495-X.
   Google Scholar
• Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 2009;86(4):328–44. doi:10.1002/bdrb.20201.
   PubMed Web of Science ®Google Scholar
• Nonclinical Evaluation for Anticancer Pharmaceuticals. ICH guideline S9. International Council for Harmonisation; 2009. https://database.ich.org/sites/default/files/S9_Guideline.pdf.
   Google Scholar
• Questions and Answers Nonclinical Evaluation for Anticancer Pharmaceuticals. ICH document S9 Q&A. International Council for Harmonisation; 2018. https://database.ich.org/sites/default/files/S9_Q%26As_Q%26As.pdf.
   Google Scholar
• CDER Pharmacology Review BLA 761036. U.S. food and drug administration. 2015. [accessed 2019 Nov 8]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/761036Orig1s000PharmR.pdf.
   Google Scholar
• Rocca M, Morford LL, Blanset D, Halpern WG, Cavagnao J, Bowman CJ. Applying a weight of evidence approach to the evaluation of developmental toxicity of biopharmaceuticals. Regulatory Toxicology and Pharmacology. 2018;98:69–79. doi:10.1016/j.yrtph.2018.07.006.
   PubMed Web of Science ®Google Scholar
• Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. ICH guideline S6(R1). International Council for Harmonisation; 2011. https://database.ich.org/sites/default/files/S6_R1_Guideline_0.pdf.
   Google Scholar
• Detection of toxicity to reproduction for medicinal products & toxicity to male fertility. ICH guideline S5(R2). European Medicines Agency; 1993. [accessed 2019 Nov 8]. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-s-5-r2-detection-toxicity-reproduction-medicinal-products-toxicity-male-fertility-step-5_en.pdf.
   Google Scholar
• Detection of toxicity to reproduction for human pharmaceuticals. ICH guideline S5(R3). International Council for Harmonisation; 2019. Accessed 2019 Nov 11. https://www.ich.org/page/safety-guidelines.
   Google Scholar
• Nonclinical safety testing in support of development of paediatric medicines. ICH draft guideline S11 step 2b. European Medicines Agency; 2018. [accessed 2019 Nov 9]. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-s11-nonclinical-safety-testing-support-development-paediatric-medicines-step-2b-draft_.pdf.
   Google Scholar
• Guidance for industry: considerations for developmental toxicity studies for preventive and therapeutic vaccines for infectious disease indications. FDA. 2006. [accessed 2019 Nov 11]. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm092170.pdf.
   Google Scholar
• Guideline on Strategies to Identify and Mitigate Risks for First-In-Human Clinical Trials with Investigational Medicinal Products. European medicines agency. 2007. [accessed 2019 Nov 12]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-mitigate-risks-first-human-clinical-trials-investigational-medicinal_en.pdf.
   Google Scholar
• Guideline on Strategies to Identify and Mitigate Risks for First-In-Human Clinical Trials with Investigational Medicinal Products. European medicines agency. Revision 1, 2017 [accessed 2019 Nov 8]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-mitigate-risks-first-human-early-clinical-trials-investigational_en.pdf.
   Google Scholar
• Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA. 1989;86(16):6077–81. doi:10.1073/pnas.86.16.6077.
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P, Chong W, Ascadi G, Jani A. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949):1465–68. doi:10.1126/science.1690918.
   PubMed Web of Science ®Google Scholar
• Reflection paper on the qualification of non-genotoxic impurities (Draft). European medicines agency. 2018. [accessed 2019 Nov 11]. EMA/CHMP/SWP/545588/2017, https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-qualification-non-genotoxic-impurities_en.pdf.
   Google Scholar
• Reviewing the use of alternative methods in biomedical research. The JRC’s EU reference laboratory for alternatives to animal testing (EURL ECVAM). European Commission; 2018 [accessed 2019 Nov 12]. https://ec.europa.eu/jrc/en/science-update/alternative-methods-biomedical-research.
   Google Scholar
• Zuang V, Viegas Barroso JF, Belz S, Berggren E, Bernasconi C, Bopp S, Bouhifd M, Bowe G, Campia I, Casati S. EURL ECVAM Status Report on the Development, Validation and Regulatory Acceptance of Alternative Methods and Approaches (2017), EUR 28823, Luxembourg (LUX/Luxembourg): Publications Office of the European Union. 2017. http://publications.jrc.ec.europa.eu/repository/handle/JRC108831.
   Google Scholar
• Zuang V, Dura A, Asturiol BD, Viegas Barroso FF, Batista Leite S, Belz S, Berggren E, Bernasconi C, Bopp S, Bouhifd M. EURL ECVAM Status Report on the Development, Validation and Regulatory Acceptance of Alternative Methods and Approaches (2018), EUR 29455. Luxembourg (LUX/Luxembourg): Publications Office of the European Union, 2018. http://publications.jrc.ec.europa.eu/repository/handle/JRC113594.
   Google Scholar
• Summary Report of the Heads of Medicines Agencies (HMA) - EMA Joint Big Data task force. European Medicines Agency; 2019 Feb 13. https://www.ema.europa.eu/en/documents/minutes/hma/ema-joint-task-force-big-data-summary-report_en.pdf.
   Google Scholar
• Predictive safety testing consortium. Homepage. Critical Path Institute; 2006 Mar 16. https://c-path.org/programs/pstc/.
   Google Scholar
• Paini A, Leonard JA, Joossens E, Bessems JGM, Desalegn A, Dorne JL, Gosling JP, Heringa M, Klaric M, Kliment T. Next generation physiologically based kinetic (NG-PBK) models in support of regulatory decision making. Computational Toxicology. 2019;9:61–72. doi:10.1016/j.comtox.2018.11.002.
   PubMedGoogle Scholar
• Rao M, Gupta R, Liguori M, Hu M, Huang X, Mantena S, Mittelstadt SW, Blomme EAG, Van Vleet TR. Novel computational approach to predict off-target interactions for small molecules. Front Big Data. 2019;2:25. doi:10.3389/fdata.
   PubMedGoogle Scholar
• Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133–50. doi:10.1038/s41568-019-0116-x.
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis G, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–80. doi:10.1038/s41571-019-0218-0.
   PubMed Web of Science ®Google Scholar
• Saber H, Gudi R, Manning M, Wearne E, Leighton JK. An FDA oncology analysis of immune activating products and first-in-human dose selection. Regul Toxicol Pharmacol. 2016;81:448–56. doi:10.1016/j.yrtph.2016.10.002.
   PubMed Web of Science ®Google Scholar
• Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273–86. doi:10.1093/biostatistics/kxx069.
   PubMed Web of Science ®Google Scholar
• Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5(197):197ra103. doi:10.1126/scitranslmed.3006034.
   PubMed Web of Science ®Google Scholar
• Sanderson JP, Crowley DJ, Wiedermann GE, Quinn LL, Crossland KL, Tunbridge HM, Cornforth TV, Barnes CS, Ahmed T, Howe K. Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy. OncoImmunology. 2019 Nov;9(1):1682381. doi:10.1080/2162402X.2019.1682381
   PubMedGoogle Scholar
• Koledova Z. 3D cell culture: an introduction. Methods Mol Biol. 2017;1612:1–11. doi:10.1007/978-1-4939-7021-6_1.
   PubMedGoogle Scholar
• IMI-TRISTAN. Innovative medicines initiative - translational imaging in drug safety assessment homepage. Bayer AG; [accessed 2019 Nov 12]. https://www.imi-tristan.eu/.
   Google Scholar
• Kenna JG, Waterton JC, Baudy A, Galetin A, Hines CDG, Hockings P, Patel M, Scotcher D, Sourbon S, Ziemian S. Methods in pharmacology and toxicology, New York, NY, humana press, noninvasive preclinical and clinical imaging of liver transporter function relevant to drug-induced liver injury. Drug-Induced Liver Toxicity. 2018:125–50. doi:10.1007/978-1-4939-7677-5_30.
   Google Scholar
• Li Y, Mention JJ, Court N, Masse-Ranson G, Toubert A, Spits H, Legrand N, Corcuff E, Strick-Marchand H, Di Santo JP. A novel Flt3-deficient HIS mouse model with selective enhancement of human DC development. Eur J Immunol. 2016. doi:10.1002/eji.201546132.
   Google Scholar
• Giese C, Demmler CD, Ammer R, Hartmann S, Lubitz A, Miller L, Müller R, Marx U. A human lymph node in vitro - challenges and progress. Artif Organs. 2006;30(10):803–08. doi:10.1111/j.1525-1594.2006.00303.x.
   PubMed Web of Science ®Google Scholar
• Morgan H, Tseng SY, Gallais Y, Leineweber M, Buchmann P, Riccardi S, Nabhan M, Lo J, Gani Z, Szely N. Evaluation of in vitro assays to assess the modulation of dendritic cells functions by therapeutic antibodies and aggregates. Front Immunol. 2019;10:1–14. doi:10.3389/fimmu.2019.00601.
   PubMed Web of Science ®Google Scholar
• Hamze M, Meunier S, Karle A, Gdoura A, Goudet A, Szely N, Pallardy M, Carbonnel F, Spindeldreher S, Mariette X. Characterization of CD4 T Cell epitopes of infliximab and rituximab identified from healthy donors. Front Immunol. 2017 May 05;8. doi:10.3389/fimmu.2017.00500.
   Google Scholar
• Spindeldreher S, Karle A, Correia E, Tenon M, Gottlieb S, Huber T, Maillere B, Kolbinger F. T Cell epitope mapping of Secukinumab and Ixekizumab in healthy donors. MAbs. 2020;12(1):1707418. doi:10.1080/19420862.2019.1707418.
   PubMed Web of Science ®Google Scholar
• Drake III DR, Nguyen MN, Kachurin A, Wittman V, Parkhill R, Moser JM, Burdin N, Moreau M, Mistretta N, Byers AM. Abstract. In vitro biomimetic model of the human immune system for predictive vaccine assessments. DISRUPTIVE SCIENCE AND TECHNOLOGY. 2012;1:28–40. doi:10.1089/dst.2012.0006.
   Google Scholar
• Higbee RG, Byers AM, Dhir V, Drake D, Fahlenkamp HG, Gangur J, Kachurin A, Kachurina O, Leistritz D, Ma Y. An immunologic model for rapid vaccine assessment - a clinical trial in a test tube. Altern Lab Anim. 2009;37(Suppl 1_suppl):19–27. doi:10.1177/026119290903701S05.
   PubMedGoogle Scholar
• Schanen BC, De Groot AS, Moise L, Ardito M, McClaine E, Martin W, Wittman V, Warren WL, DrakeIII DR. Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus. Vaccine. 2011;29(17):3299–309. doi:10.1016/j.vaccine.2011.02.019.
   PubMed Web of Science ®Google Scholar
• Bessa J, Boeckle S, Beck H, Buckel T, Schlicht S, Ebeling M, Kiialainen A, Koulov A, Boll B, Weiser T. The Immunogenicity of antibody aggregates in a novel transgenic mouse model. Pharm Res. 2015;32(7):2344–59. doi:10.1007/s11095-015-1627-0.
   PubMed Web of Science ®Google Scholar
• Expert Scientific Group on Phase One Clinical Trials. Expert Scientific Group on Phase One Clinical Trials: Final Report. London (UK): The Stationery Office; 2006.
   Google Scholar
• FDA: guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005 Jul. https://www.fda.gov/media/72309/download.
   Google Scholar
• An B, Zhang M, Qu J. Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry. Drug Metabolism and Disposition. 2014;42(11):1858–66. http://dmd.aspetjournals.org/content/42/11/1858.pdf. doi:10.1124/dmd.114.058917.
   PubMedGoogle Scholar
• Law WS, Genin JC, Miess C, Treton G, Warren AP, Lloyd P, Krantz C. Use of generic LC–MS/MS assays to characterize atypical PK profile of a biotherapeutic monoclonal antibody. Bioanalysis. 2014;6(23):3225–35. https://future-science.com/doi/ 10.4155/bio.14.167.pdf.
   PubMed Web of Science ®Google Scholar
• Boyne M, Bose R Target Proteins: bottom‐up and top‐down proteomics. In: Gross ML, Chen G, Pramanik BN, editors. Protein and Peptide Mass Spectrometry in Drug Discovery. 2011. p. 89–100. https://onlinelibrary.wiley.com/doi/pdf/ 10.1002/9781118116555.ch3.
   Google Scholar
• Ramagiri S, Hybridizing MI. LBA with LC-MS/MS: the new norm for biologics quantification. Bioanalysis. 2016;8(6):483–86. doi:10.4155/bio.16.9.
   PubMed Web of Science ®Google Scholar
• An B, Zhang M, Qu J. LC/MS versus immune‐based bioanalytical methods in quantitation of Therapeutic Biologics in biological matrices. In: Gad SC, editor. Pharmaceutical Sciences Encyclopedia. 2015. p. 313–329. doi:10.1002/9780470571224.pse556.
   Google Scholar
• Zheng J, Mehl JT, Zhu Y, Xin B, Olah TV. Application and challenges in using LC-MS assays for absolute quantitative analysis of therapeutic proteins in drug discovery. Bioanalysis. 2014;6(6):859–79. doi:10.4155/bio.14.36.
   PubMed Web of Science ®Google Scholar
• Xu W, Jiang H, Titsch C, Gadkari S, Batog A, Wang B, Pillutla R. Concerted application of LC–MS and ligand binding assays to better understand exposure of a large molecule drug. Bioanalysis. 2018;10(16):1261–72. https://ncbi.nlm.nih.gov/pubmed/29923414.pdf. doi:10.4155/bio-2018-0108.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kelley M, King L, Yang J, Salimi-Moosavi H, Tang MT, Rogers C. Bioanalytical approaches to quantify “Total” and “Free” therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. Aaps Journal. 2011;13(1):99–110. https://ncbi.nlm.nih.gov/pmc/articles/pmc3032085.pdf. doi:10.1208/s12248-011-9251-3.
   PubMed Web of Science ®Google Scholar
• Haberger MB. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies Susceptibility vs. functionality of critical quality attributes. mAbs. 2014;6(2):327–39. doi:10.4161/mabs.27876.
   PubMed Web of Science ®Google Scholar
• Yu MB. Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans. mAbs. 2012;4(4):475–87. doi:10.4161/mabs.20737.
   PubMed Web of Science ®Google Scholar
• Xu X, Qiu H, Li N. LC-MS multi-attribute method for characterization of biologics. Journal of Applied Bioanalysis. 2017;3(2):21–25. http://betasciencepress.com/index.php/jab17003.pdf. doi:10.17145/jab.17.003.
   Google Scholar
• Sydow JL. Structure-based prediction of Asparagine and Aspartate degradation sites in antibody Variable Regions. PLOS ONE. 2014;9(6):e100736. doi:10.1371/journal.pone.0100736.
   PubMed Web of Science ®Google Scholar
• Bults PB. LC-MS/MS-based monitoring of in vivo Protein biotransformation: quantitative determination of Trastuzumab and its deamidation products in human plasma. Anal Chem. 2016;88(3):1871–77. doi:10.1021/acs.analchem.5b04276.
   PubMed Web of Science ®Google Scholar
• Higel FS. N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. European Journal of Pharmaceutics and Biopharmaceutics. 2016;100:94–100. doi:10.1016/j.ejpb.20.
   PubMed Web of Science ®Google Scholar
• Zhou QQ. The mechanistic impact of N-Glycosylation on stability, pharmacokinetics, and immunogenicity of therapeutic Proteins. J Pharm Sci. 2019;108(4):1366–77. doi:10.1016/j.xphs.2018.11.029.
   PubMed Web of Science ®Google Scholar
• Thorneloe KS, Sepp A, Zhang S, Galinanes-Garcia L, Galette P, Al-Azzam W, Vugts DJ, van Dongen G, Elsinga P, Wiegers J. The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans. EJNMMI Res. 2019;9(1):45. doi:10.1186/s13550-019-0514-9.
   PubMedGoogle Scholar
• Schadt S, Hauri S, Lopes F, Edelmann MR, Staack RF, Villaseñor R. Are biotransformation studies of therapeutic Proteins needed? scientific considerations and technical challenges. Drug Metabolism and Disposition. 2019;47(12):1443–56. doi:10.1124/dmd.119.088997.
   PubMed Web of Science ®Google Scholar